Biotechnology Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years – Novartis (NYSE:NVS) Read more
Stockmarkets Explainer-Why are US pharmacy benefit managers under fire? Reuters via biedexmarkets.com Read more
Biotechnology Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy – Cartesian Therapeutics (NASDAQ:RNAC) Read more
Biotechnology Bristol Myers Squibb’s Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation – Bristol-Myers Squibb (NYSE:BMY) Read more
Cannabis California’s Weed Sales Decline: Market Ripe For Consolidation, Biggest Companies Likely To Benefit – Gold Flora (OTC:GRAM), Glass House Brands (OTC:GHBWF) Read more
Biotechnology AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer – AstraZeneca (NASDAQ:AZN) Read more
Biotechnology Investors Cheer Acelyrin’s Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients – Acelyrin (NASDAQ:SLRN) Read more